Microbot Medical Says Plans To Submit An Investigational Device Exemption Application To The FDA For A Pivotal Clinical Trial In Humans
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical Inc. (NASDAQ:MBOT) has announced successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study. The company plans to submit an Investigational Device Exemption (IDE) application to the FDA for a pivotal clinical trial in humans, subject to the final report and the completion of the verification and validation process.
October 17, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical's successful initial outcomes of the LIBERTY Robotic Surgical System in its pre-clinical study could potentially lead to a pivotal clinical trial in humans, pending FDA approval.
The successful initial outcomes of the LIBERTY Robotic Surgical System in its pre-clinical study is a positive development for Microbot Medical. If the company receives FDA approval for its IDE application, it could potentially commence a pivotal clinical trial in humans, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100